Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.
Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland.
Ann Thorac Surg. 2022 Jan;113(1):146-156. doi: 10.1016/j.athoracsur.2020.12.059. Epub 2021 Feb 3.
The optimal surgical strategy (repair vs replacement) for patients with secondary mitral (MV) regurgitation is questionable.
Patients who underwent MV repair or replacement for functional or ischemic mitral regurgitation between 2006 and 2017 were identified in Polish National Registry of Cardiac Surgery Procedures. Patients, who underwent additional procedures other than coronary artery bypass grafting or tricuspid valve surgery, as well as redo or emergency cases, were excluded. The long-term survival was verified based on National Health Fund registry. The survival was compared between MV repair and replacement both in the whole cohort and after propensity score matching. The Cox regression was used to seek for independent predictors of survival.
Of 7633 identified patients, 1793 (23%) underwent MV replacement and 5840 (77%) underwent MV repair. Coronary artery bypass surgery was performed together with MV repair in 3992 (69%) patients and together with MV replacement in 915 (52%) patients (P < .001). Tricuspid valve surgery was added to 1393 (24%) MV repairs and to 561 (32%) MV replacements (P < .001). The crude actuarial 5-year survival was 71% (95% confidence interval [CI], 70%-72%) in the repair group and 66% (95% CI, 63%-68%) in the replacement group (P < .001). MV replacement was an independent predictor of mortality (hazard ratio, 1.32; 95% CI, 1.17-1.49) (P < .001) in Cox regression modeling. In the propensity-matched cohort (1105 pairs), the long-term mortality was also significantly higher in the replacement group (hazard ratio, 1.24; 95% CI, 1.06-1.45; P = .008).
Repair of secondary mitral regurgitation has an associated survival benefit compared with MV replacement.
对于继发性二尖瓣(MV)反流患者,最佳手术策略(修复与置换)仍存在争议。
在波兰国家心脏手术程序注册中心,确定了 2006 年至 2017 年间因功能性或缺血性二尖瓣反流而行 MV 修复或置换的患者。排除了接受冠状动脉旁路移植术或三尖瓣手术以外的其他附加手术、再次手术或急诊手术的患者。使用国家卫生基金登记处验证长期生存率。在整个队列和倾向评分匹配后,比较 MV 修复和置换的生存率。使用 Cox 回归寻找生存率的独立预测因素。
在 7633 例患者中,1793 例(23%)接受 MV 置换,5840 例(77%)接受 MV 修复。MV 修复时同时行冠状动脉旁路手术的患者有 3992 例(69%),MV 置换时同时行冠状动脉旁路手术的患者有 915 例(52%)(P<0.001)。MV 修复时同时行三尖瓣手术的患者有 1393 例(24%),MV 置换时同时行三尖瓣手术的患者有 561 例(32%)(P<0.001)。修复组的 5 年粗生存率为 71%(95%可信区间[CI],70%-72%),置换组为 66%(95% CI,63%-68%)(P<0.001)。Cox 回归模型显示,MV 置换是死亡率的独立预测因素(风险比,1.32;95% CI,1.17-1.49)(P<0.001)。在倾向评分匹配的队列(1105 对)中,置换组的长期死亡率也显著较高(风险比,1.24;95% CI,1.06-1.45;P=0.008)。
与 MV 置换相比,修复继发性二尖瓣反流可带来生存获益。